Thiamphenicol glycinate acetylcysteine

Thiamphenicol glycinate acetylcysteine
	Chemical structures of thiamphenicol glycinate (top) and acetylcysteine (bottom)
Combination of
Thiamphenicol glycinate	Antibiotic
Acetylcysteine	Mucoactive agent
Identifiers
CAS Number	20192-91-0;
PubChem CID	44147002;
UNII	7I3XBP3IFP;
CompTox Dashboard (EPA)	DTXSID10942260 ;
ECHA InfoCard	100.039.597
Chemical and physical data
Formula	C19H27Cl2N3O9S2
Molar mass	576.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)NC(CS)C(=O)O.CS(=O)(=O)C1=CC=C(C=C1)C(C(COC(=O)CN)NC(=O)C(Cl)Cl)O;

Thiamphenicol glycinate acetylcysteine (TGA) is a pharmaceutical drug that is a combination of thiamphenicol glycinate ester (TAFGE), which is a derivative of the antibiotic thiamphenicol, and N-acetylcysteine (NAC), which is a mucus-thinning drug. Upon contact with tissue esterases, TGA releases both TAFGE and NAC. As a standalone medication, NAC is widely used in respiratory tract infections for its mucolytic activity.^[1]

^ Serra A, Schito GC, Nicoletti G, Fadda G (2007). "A therapeutic approach in the treatment of infections of the upper airways: thiamphenicol glycinate acetylcysteinate in sequential treatment (systemic-inhalatory route)". International Journal of Immunopathology and Pharmacology. 20 (3): 607–617. doi:10.1177/039463200702000319. PMID 17880774.

[pmid17880774-1] Serra A, Schito GC, Nicoletti G, Fadda G (2007). "A therapeutic approach in the treatment of infections of the upper airways: thiamphenicol glycinate acetylcysteinate in sequential treatment (systemic-inhalatory route)". International Journal of Immunopathology and Pharmacology. 20 (3): 607–617. doi:10.1177/039463200702000319. PMID 17880774.

[1]